항암 화학요법을 받는 유방암 환자의 피로 예측요인

손선미(Son, Sun mi),이지현(Lee, Ji Hyun) 고신대학교 전인간호과학연구소 2015 전인간호과학학술지 Vol.7 No.-

Purpose: This study was to investigate on the predictors of fatigue and to offer the basic data for nursing intervention of breast cancer patients undergoing chemotherapy. Methods: The subjects were 166 patients at ambulatory care unit in a university hospital in B city. The data was collected from February 4 to March 11, 2009. Results: Fatigue of the subjects showed statistically significant differences according to educational level(F=5.633, p<.001), age(F=3.008, p=.032), the frequency of chemotherapy((F=2.891, p=.037), and pain(F=11.146, p<.001). Fatigue showed an inverse relationship in a medium degree with quality of life(r= - .556, p= .000) and quality of sleep(r= - .393, p= .000). The study on the overall influences of the factors on fatigue with the help of stepwise multiple regression analysis revealed that spiritual dimension of quality of life was the most powerful factor among the factors on subjets fatigue by 32.3%, followed by the side effects of chemotherapy, depression, physical dimension of quality of life, frequency of chemotherapy and duration of Chemotherapy by 56.3%. Conclusion: Influences of the factors on fatigue of the breast cancer patients undergoing chemotherapy experienced moderate level of quality of life, side effect, depression, and the frequency and duration of chemotherapy.

통합교육에 대한 교사와 학부모의 인식에 관한 질적 분석

손선미 ( Sun Mi Son ),박남수 ( Nam Su Park ) 한국정신지체아교육학회 2007 지적장애연구 Vol.9 No.3

조리방법에 따른 참깨의 알레르기 항원성 비교

이경은 ( Kyung Eun Lee ),홍정연 ( Jung Yeon Hong ),손선미 ( Sun Mi Son ),박선희 ( Sun Hee Park ),이상일 ( Sang Il Lee ),손명현 ( Myung Hyun Sohn ),김규언 ( Kyu Earn Kim ),김경원 ( Kyung Won Kim ) 대한소아알레르기호흡기학회(구 대한소아알레르기 및 호흡기학회) 2009 소아알레르기 및 호흡기학회지 Vol.19 No.1

목적: 본 연구에서는 참깨 알레르겐의 구성단백을 알아보고 조리방법에 따른 항원성의 변화를 비교하고자 하였으며, 참깨 특이 IgE 항체 수치가 높은 환자들의 혈청을 이용하여 IgE와 결합하는 알레르겐 내 구성단백들을 조사하고자 하였다. 방법: 참깨를 다양한 방법(볶기, 식물성 기름과 볶기, 삶기)으로 조리한 후 각각의 조항원을 제조하고 SDS-PAGE를 통해 그 단백분포를 비교하였다. 그리고 알레르기 환자를 대상으로 시행한 CAP test를 기초로 참깨 알레르겐에 감작된 환자의 혈청을 수집하고 immunoblot 분석을 시행하여 특이 IgE 결합능을 비교해 보았다. 결과: 조리하지 않은 참깨의 경우 SDS-PAGE상에서 6-115 kD 크기에 해당하는 많은 단백 띠들이 관찰되었다. 이 중에서도 중요 참깨 알레르겐들로 알려져 있는 7, 9, 12, 15, 17 kD 단백 띠들이 존재함을 관찰할 수 있었다. 각각의 조리한 참깨들을 비교해 본 결과, 볶거나 식물성 기름과 함께 볶은 경우 거의 대부분의 단백 띠들이 소실되었으나 삶은 경우에는 보다 선명한 다양한 크기의 단백 띠들이 재구성됨을 알 수 있었다. 또한 참깨를 삶은 후 분리한 상층액에서도 특징적으로 6 kD부근에 단백 띠들이 관찰되었다. 참깨에 특이적인 환자혈청들을 사용하여 IgE immunoblot 분석을 실시한 결과 조리하지 않은 참깨는 삶거나 식물성 기름과 볶은 참깨와 함께 공통적으로 7 kD 또는 37 kD에 특이적으로 결합한 IgE 단백띠를 형성하였다. 결론: 참깨의 경우 조리방법에 따라 항원성의 변화가 있으며, 특히 조리하지 않거나 또는 삶은 경우에 참깨 특이 IgE 항체 반응은 다른 조리방법들보다 상대적으로 강하게 나타났으며 이와 같은 강한 항원성은 참깨에 대한 감작률을 높일 수 있다고 생각된다. Purpose: There has been a significant increase in the number on reports of hypersensitivity to sesame, probably because of its use in international fast-food and bakery products. Thus, we have investigated whether various cooking methods affect the allergenicity of sesame. Methods: Sesame seeds were roasted, boiled or fried with vegetable oil, and then their proteins were each extracted. The proteins were separated by sodium dodecyl sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE) and detection of immunoglobulin (Ig) E specific to sesame seed proteins was performed with Western blotting using 6 sera. Results: SDS-PAGE of raw sesame proteins showed various-sized bands including 7, 9, 12, 15 and 17 kD known as major allergens. While only few protein bands remained in roasted or fried sesame seeds, some protein bands sized under 15 kD were observed in the boiled sesame seeds and their soup. The pooled sera yielded IgE-specific reaction with 7 kD in raw and boiled, and 37 kD in fried and boiled sesame proteins. Conclusion: These findings suggest that the cooking methods may change the allergenicity of sesame seed proteins. [Pediatr Allergy Respir Dis(Korea) 2009;19:56-62]

2세 남아에서 발견된 들깨 알레르기 1례

송지은 ( Ji Eun Song ),이재랑 ( Jae Rang Lee ),박여훈 ( Yeo Hoon Park ),홍정연 ( Jung Yeon Hong ),손선미 ( Sun Mi Son ),김경원 ( Kyung Won Kim ),고홍 ( Hong Koh ),정기섭 ( Ki Sup Chung ),손명현 ( Myung Hyun Sohn ),김규언 ( Kyu Ea 대한소아알레르기호흡기학회(구 대한소아알레르기 및 호흡기학회) 2009 소아알레르기 및 호흡기학회지 Vol.19 No.1

저자들은 아토피 피부염이 있으며 난백, 땅콩 등에 알레르기가 있는 유아에서 이유기에 처음으로 섭취한 들깨에 의해 심한 소화기 증상이 발생했던 들깨 알레르기 환아 1례를 경험하였기에 들깨 단백분석 및 환아 혈청 내 특이 IgE와의 immunoblot 분석과 함께 보고하는 바이다. Even though perilla is one of the most commonly consumed grain in Asia including Korea, perilla allergy is rare. A 2 year-old boy had erythematous popular urticaria on his whole body, as well as vomiting and diarrhea after ingestion of boiled perilla. On the second day of admission, old blood clots in the vomitus and blood tinged stool were shown. He underwent an esophago gastro duodenoscopy which showed a large duonenal ulcer. After treatment, his general condition improved. We report a case of perilla allergy with brief review of related literature. [Pediatr Allergy Respir Dis(Korea) 2009;19:78-83]

피브린 고분자와 반원상 연골세포를 이용한 손상된 가토 반원상 연골의 재생

손선미,이재선,최차용,박종용,김병수,박정호 대한정형외과연구학회 2003 대한정형외과연구학회지 Vol.6 No.2

디스그렌 캅셀(트리플루살 300 mg)에 대한 티그린 캅셀의 생물학적 동등성

김수진,심영순,손선미,임동구,문재동,이용복 전남대학교 약품개발연구소 1999 약품개발연구지 Vol.8 No.1

Triflusal is a new antithrombotic agent which inhibits both platelet cyclooxygenase and c-AMP phosphodiesterase activity. The purpose of the present study was to evaluate the bioequivalence of two triflusal capsules, Disgren^(TM) (Myung-In Pharmaceutical Co., Ltd.) and Tigrin^(TM) (Hana Pharmaceutical Co., Ltd.) according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 22.94±11.83 in age and 63.71±10.43 ㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one capsule containing 300 ㎎ of triflusal was orally administered, blood was taken at predetermined time intervals and the concentrations of triflusal in serum were determined using HPLC method with UV detector Pharmacokinetic parameters such as AUC_t, C_(max) and T_(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t, C_(max) and T_(max) between two capsules were -0.30%, 0.81% and -3.03%, respectively when calculated against the Disgren^(TM) capsule. The powers (1-β) for AUC_t, C_(max) and T_(max) were 98.29%, 84.73% and 81.02%, respectively. Minimum detectable differences (Δ) at α=0.1 and 1-β=0.8 were all less than 20% (e.g., 12.91%, 18.46% and 19.65% for AUC_t, C_(max) and T_(max) respectively). The 90% confidence intervals were all within ±20%(e.g., -8.97∼8.37. -11.58∼13.22 and -16.23∼10.17 for AUC_t, C_(max) and T_(max) respectively). All of the above parameters (1-β, Δ and 90% confidence intervals) met the criteria of KFDA for bioequivalence, indicating that Tigrin^(TM) capsule is bioequivalent to Disgren^(TM) capsule.

디스그렌 캅셀(트리플루살 300mg)에 대한 티그린 캅셀의 생물학적 동등성

김수진,심영순,손선미,임동구,문재동,이용복 전남대학교 약품개발연구소 2000 약품개발연구지 Vol.9 No.1

Triflusal is a new antithrombotic agent which inhibits both platelet cyclooxygenase and c-AMP phosphodiesterase activity. The purpose of the present study was to evaluate the bioequivalence of two triflusal capsules, Disgren^(TM) (Myung-In Pharmaceutical Co., Ltd.) and Tigrin^(TM) (Hens Pharmaceutical Co., Ltd.) according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 22.94±1.83 in age and 63.71±10.43 ㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one capsule containing 300 ㎎ of triflusal was orally administered, blood was taken at predetermined time intervals and the concentrations of triflusal in serum were determined using HPLC method with UV detector. Pharmacokinetic parameters such as AUC_t, C_(max) and T_(max) , were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t, C_(max) and T_(max) , between two capsules were -0.30%, 0.81% and -3.03%, respectively when calculated against the Disgren^(TM) capsule. The powers (1-β) for AUC_t, C_(max) and T_(max) , were 98.29%, 84.73% and 81.02%, respectively. Minimum detectable differences (Δ) at α=0.1 and 1-β=0.8 were all less than 20% (e.g.. 12.91%, 18.46% and 19.65% for AUC_t, C_(max) and T_(max), respectively). The 90% confidence intervals were all within 120%(e.g., -8.97∼8.37, -11.58∼13.22 and -16.23-10.17 for AUC_t, C_(max) and T_(max) , respectively). All of the above parameters (1-β, Δ and 90% confidence intervals) met the criteria of KFDA for bioequivalence, indicating that Tigrin^(TM) capsule is bioequivalent to Disgren^(TM) capsule.

디스그렌 캅셀(트리플루살 300 mg)에 대한 키그린 캅셀의 생물학적 동등성

김수진,이용복,임동구,문재동,심영순,손선미 한국약제학회 1999 Journal of Pharmaceutical Investigation Vol.29 No.4

Triflusal is a new antithrombotic agent which inhibits both platelet cyclooxygenase and c-AMP phosphodiesterase activity. The purpose of the present study was to evaluate the bioequivalence of two triflusal capsules, Disgren^(TM) (Myung-In Pharmaceutical Co., Ltd.) and Tigrin^(TM) (Hana Pharmaceutical Co., Ltd.) according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 22.94±1.83 in age and 63.71±10.43 ㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one capsule containing 300 ㎎ of triflusal was orally administered, blood was taken at predetermined time intervals and the concentrations of triflusal in serum were determined using HPLC method with UV detector. Pharmacokinetic parameters such as AUC_t, C_(max) and T_(max) were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t, C_(max) and T_(max) between two capsules were -0.30%, 0.81% and -3.03%, respectively when calculated against the Disgren^(TM) capsule: The powers (1-β) for AUC_t, C_(max) and T_(max) were 98.29%, 84.73% and 81.02%, respectively. Minimum detectable differences (Δ) at α=0.l and 1-β=0.8 were all less than 20% (e.g., 12.91 %, 18.46% and 19.65% for AUC_t; C_(max) and T_(max), respectively). The 90% confidence intervals were all within ±20%(e.g., -8.97∼8.37, -11.58∼13.22 and -16.23∼10.17 for AUC_t, C_(max) and T_(max), respectively). All of the above parameters (1-β, Δ and 90% confidence intervals) met the criteria of KFDA for bioequivalence, indicating that Tigrin^(TM) capsule is bioequivalent to Disgren^(TM) capsule.